Table 4.
Disease characteristics of patients with a change in MRI‐detected axial SpA status at 3‐month or 1‐year follow‐upsa
| MRI‐detected axial SpA status | Radiographically detected sacroliitisb | HLA–B27 positive | Age/sex | SpA features at baselinec | SpA features at follow‐upc | CRP level at baseline | CRP level at follow‐up | ASDAS at baseline | ASDAS at follow‐up | Medication at baseline | Medication at follow‐up | SPARCC score at baseline (reader 1/ reader 2) | SPARCC score at follow‐up (reader 1/ reader 2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline negative/ 3‐month positive | |||||||||||||
| Patient 1 | Yes | Yes | 19/M | 1, 2 | Idem | 3 | 5 | 0.8 | – | – | – | 0/0 | 5/6 |
| Patient 2 | No | No | 38/F | 1, 3 | Idem | 3 | 5 | – | – | NSAID | NSAID | 1/1 | 2/2 |
| Patient 3 | No | Yes | 25/M | 2, 8 | Idem + 9 | 6 | 4 | 1.6 | – | – | NSAID | 0/0 | 10/7 |
| Patient 4 | No | No | 29/F | 1 | Idem | 3 | 1 | 0.9 | – | – | – | 0/0 | 9/12 |
| Patient 5 | No | Yes | 26/M | 1, 2 | Idem + 9 | 3 | 3 | 1.6 | – | – | NSAID | 0/0 | 5/5 |
| Baseline positive/ 3‐month negative | |||||||||||||
| Patient 6 | Yes | Yes | 21/M | 1, 9 | Idem | 6 | 14 | 1.4 | – | NSAID | NSAID | 3/5 | 0/3 |
| Patient 7 | No | Yes | 32/M | 1, 6, 9 | Idem | 3 | 4 | 3.8 | – | NSAID | NSAID | 2/4 | 0/0 |
| Patient 8 | No | Yes | 31/M | 1, 6, 8, 9 | Idem | 9 | 2 | 3.4 | – | NSAID | NSAID | 2/2 | 0/0 |
| Baseline negative/ 1‐year positive | |||||||||||||
| Patient 9 | No | Yes | 21/F | 1, 2, 5, 9 | Idem | 3 | 3 | 2.2 | 2.9 | NSAID | NSAID | 0/0 | 4/3 |
| Patient 10 | Yes | Yes | 33/M | 1, 4 | Idem + 9 | 3 | 3 | 0.9 | 2.3 | – | NSAID | 0/0 | 5/6 |
| Patient 11 | Yes | Yes | 19/M | 1, 2 | Idem | 3 | 1 | 0.8 | 0.4 | – | NSAID | 0/0 | 16/18 |
| Patient 12 | No | Yes | 31/M | 1,2 | Idem | 3 | 3 | 2.4 | 2.4 | NSAID | NSAID | 0/2 | 2/3 |
| Patient 13 | No | Yes | 32/M | 1 | Idem | 13 | 9 | 3.0 | 3.2 | NSAID | NSAID | 0/0 | 3/2 |
| Patient 14 | No | Yes | 19/F | 2 | Idem | 4 | 1 | 3.3 | 1.2 | NSAID | NSAID | 0/0 | 2/2 |
| Patient 15 | No | No | 32/F | 1, 2, 6, 9 | Idem | 1 | 1 | 2.7 | – | NSAID | NSAID | 1/0 | 5/5 |
| Patient 16 | No | Yes | 25/M | 2, 8 | Idem + 1, 7, 9 | 6 | 3 | 1.6 | – | – | NSAID | 0/0 | 10/7 |
| Patient 17 | Yes | Yes | 35/F | 9 | Idem | 3 | 10 | 2.5 | – | – | NSAID | 1/0 | 14/11 |
| Patient 18 | No | No | 29/F | 1 | Idem | 3 | 1 | 0.9 | 1.0 | – | NSAID | 0/0 | 13/16 |
| Baseline positive/ 1‐year negative | |||||||||||||
| Patient 19 | No | No | 43/F | 1, 6 | Idem + 5 | 1 | 1 | 1.4 | 1.1 | – | – | 3/2 | 0/0 |
| Patient 20 | Yes | Yes | 29/F | 1 | Idem + 9 | 1 | 1 | 1.6 | 1.4 | NSAID | NSAID + anti‐TNF | 14/14 | 0/0 |
| Patient 21 | No | Yes | 31/M | 1, 6, 8, 9 | Idem + 7 | 9 | 1 | 3.4 | 0.8 | NSAID | NSAID | 2/2 | 0/0 |
| Patient 22 | No | No | 40/F | 1 | Idem + 4, 9 | 4 | 4 | 2.1 | 3.7 | – | Anti‐TNF | 8/8 | 0/0 |
| Patient 23 | Yes | Yes | 22/M | ‐ | 1, 2, 9 | 3 | 3 | 3.1 | 2.7 | NSAID | NSAID | 9/13 | 1/0 |
| Patient 24 | No | Yes | 32/M | 1, 6, 9 | Idem + 2 | 3 | 3 | 3.8 | ‐ | NSAID | NSAID | 2/4 | 0/0 |
| Patient 25 | No | Yes | 33/M | 1, 8, 9 | Idem | 23 | 1 | 2.9 | 1.0 | NSAID | Anti‐TNF | 7/5 | 0/0 |
| Patient 26 | No | No | 46/M | 1, 9 | Idem | 4 | 4 | 2.7 | 1.6 | NSAID | NSAID | 4/2 | 1/0 |
| Patient 27 | Yes | Yes | 24/F | 2, 5, 6 | Idem + 1, 9 | 3 | 3 | 3.0 | 1.0 | NSAID | NSAID + anti‐TNF | 46/44 | 0/0 |
| Patient 28 | Yes | Yes | 42/M | 6, 9 | Idem | 1 | 1 | 3.0 | 1.0 | NSAID | NSAID | 10/9 | 0/0 |
| Patient 29 | Yes | Yes | 26/M | 1, 2 | Idem | 2 | 2 | 2.0 | 2.3 | – | NSAID | 18/16 | 2/0 |
Except where indicated otherwise, characteristics are recorded at baseline. Follow‐up data were obtained at either 3 months (patients 1–8) or 1 year (patients 9–29). MRI = magnetic resonance imaging; CRP = C‐reactive protein; ASDAS = ankylosing spondylitis disease activity score; SPARCC = Spondyloarthritis Research Consortium of Canada system.
Based on the modified New York criteria.
Spondyloarthritis (SpA) characteristics are numerically represented. 1 = inflammatory back pain; 2 = family history of SpA; 3 = uveitis; 4 = irritable bowel disease; 5 = psoriasis; 6 = enthesitis; 7 = dactylitis; 8 = peripheral arthritis; 9 = nonsteroidal antiinflammatory drug (NSAID) responsiveness; idem = same features as at baseline.